Citations

Clear

258 citation(s) found for "Ge, Tian".

Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, Joshua D. , Li, Lu , Wang, Yuxuan , Thoburn, Christopher J. , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A. , Wong, Fay , Mattox, Austin K. , Hruban, Ralph H. , Wolfgang, Christopher L. , Molin, Marco Dal , Ptak, Janine , Dobbyn, Lisa , Silliman, Natalie , Browne, J. Dale, Tie, Jeanne , Wong, Hui‐Li , Mansfield, Aaron S. , Jen, Jin , Falconi, Massimo , Allen, Peter J. , Zhou, Shibin , Díaz, Luis A. , Kinzler, Kenneth W. , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Thoburn, Christopher , Danilova, Ludmila , Douville, Christopher , Javed, Ammar A , Wong, Fay , Mattox, Austin , Wolfgang, Christopher L , Roden, Richard , Klein, Alison P , Ptak, Janine , Dobbyn, Lisa , Schaefer, Joy , Silliman, Natalie , Schoen, Robert E , Brand, Randall E , Tie, Jeanne , Wong, Hui-Li , Mansfield, Aaron S , Jen, Jin , Zhou, Shibin , Diaz, Luis A , Tomasetti, Cristian , Kinzler, Kenneth W , Vogelstein, Bert , Lennon, Anne Marie , Papadopoulos, Nickolas , Wang, Yuxuan , Afsari, Bahman , Goggins, Michael , Wang, Tian‐Li , Klein, Alison P. , Popoli, Maria , Vogelstein, Joshua T , Schoen, Robert E. , Brand, Randall E. , Gibbs, Peter , Hanash, Samir , Bettegowda, Chetan , Massimo, Falconi

Mayo Clinic

Science | January 18, 2018 | Volume: 359 | Issue: 6378 | Pages: 926-930

10.1126/science.aar3247 | PMID 29348365 Get It

SEEK and you may find cancer earlier Many cancers can be cured by surgery and/or systemic therapies when detected before they have metastasized. This clinical reality, coupled with the growing appreciation that cancer's rapid genetic evolution limits its response to drugs, have fueled interest in methodologies for earlier detection of the disease. Cohen et al. developed a noninvasive blood test, called CancerSEEK that can detect eight common human cancer types (see the Perspective by Kalinich and Haber). The test assesses eight circulating protein biomarkers and tumor-specific mutations in circulating DNA. In a study of 1000 patients previously diagnosed with cancer and 850 healthy control individuals, CancerSEEK detected cancer with a sensitivity of 69 to 98% (depending on cancer type) and 99% specificity. Science , this issue p. 926 ; see also p. 866
Fingolimod Protects Against Ischemic White Matter Damage by Modulating Microglia Toward M2 Polarization via STAT3 Pathway
Qin, Chuan , Fan, Wen-Hui, Shang, Ke , Murugan, Madhuvika , Wu, Long‐Jun , Wang, Wei , Tian, Dai‐Shi , Wu, Long-Jun , Tian, Dai-Shi , Liu, Qian

Mayo Clinic

Stroke | November 7, 2017 | Volume: 48 | Issue: 12 | Pages: 3336-3346

10.1161/strokeaha.117.018505 | PMID 29114096 Get It

Background and Purpose— White matter (WM) ischemic injury, a major neuropathological feature of cerebral small vessel diseases, is an important cause of vascular cognitive impairment in later life. The pathogenesis of demyelination after WM ischemic damage are often accompanied by microglial activation. Fingolimod (FTY720) was approved for the treatment of multiple sclerosis for its immunosuppression property. In this study, we evaluated the neuroprotective potential of FTY720 in a WM ischemia model. Methods— Chronic WM ischemic injury model was induced by bilateral carotid artery stenosis. Cognitive function, WM integrity, microglial activation, and potential pathway involved in microglial polarization were assessed after bilateral carotid artery stenosis. Results— Disruption of WM integrity was characterized by demyelination in the corpus callosum and disorganization of Ranvier nodes using Luxol fast blue staining, immunofluorescence staining, and electron microscopy. In addition, radial maze test demonstrated that working memory performance was decreased at 1-month post–bilateral carotid artery stenosis–induced injury. Interestingly, FTY720 could reduce cognitive decline and ameliorate the disruption of WM integrity. Mechanistically, cerebral hypoperfusion induced microglial activation, production of associated proinflammatory cytokines, and priming of microglial polarization toward the M1 phenotype, whereas FTY720 attenuated microglia-mediated neuroinflammation after WM ischemia and promoted oligodendrocytogenesis by shifting microglia toward M2 polarization. FTY720’s effect on microglial M2 polarization was largely suppressed by selective signal transducer and activator of transcription 3 (STAT3) blockade in vitro, revealing that FTY720-enabled shift of microglia from M1 to M2 polarization state was possibly mediated by STAT3 signaling. Conclusions— Our study suggested that FTY720 might be a potential therapeutic drug targeting brain inflammation by skewing microglia toward M2 polarization after chronic cerebral hypoperfusion.
Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
Du, Meijun , Giridhar, Karthik V. , Tian, Yijun , Tschannen, Michael, Zhu, Jing , Huang, Chiang‐Ching , Kilari, Deepak , Kohli, Manish , Wang, Liang , Giridhar, Karthik V , Kohli, Manish

Mayo Clinic

Oncotarget | July 23, 2017 | Volume: 8 | Issue: 38 | Pages: 63703-63714

10.18632/oncotarget.19476 | PMID 28969022 Get It

Cryoballoon ablation in Chinese patients with paroxysmal atrial fibrillation: 1‐year follow‐up
Ling, Tianyou , Pan, Wenqi , Lin, Changjian , Lee, Hon‐Chi, Wu, Liqun , Ling, Tian-You , Jin, Qi , Zhang, Ning

Mayo Clinic

Pacing and Clinical Electrophysiology | July 13, 2017 | Volume: 40 | Issue: 10 | Pages: 1067-1072

10.1111/pace.13157 | PMID 28703873 Get It

AbstractObjectivesWe assessed the effectiveness and safety of cryoballoon ablation (CBA) in the Chinese population with paroxysmal atrial fibrillation (AF) with a 1‐year follow‐up and determined the association of early recurrence of atrial tachyarrhythmias (ERAT) with late recurrence (LR).MethodsA total of 114 patients (age 61 ± 10 years, 78 males) with paroxysmal AF who underwent CBA were consecutively enrolled. After procedures, patients were observed for 3 days with continuous electrocardiogram monitoring in the hospital with routine follow‐up visits at 3 months, 6 months, and 1 year. Documented atrial tachyarrhythmia >30 seconds was defined as recurrence. ERAT was defined as any recurrence during the first 3 months, and LR was recurrence between 3 and 12 months.ResultsWith the first 3 months as blanking period, 76% of patients were free of LR at 12 months. Five patients (4%) experienced complications, including phrenic nerve palsy, stroke, and groin complications. Forty‐five percent of patients had ERAT in the first 3 months and 31% of patients had ERAT in the first 3 days. Patients with ERAT had higher LR rate (LRR) than those without ERAT (43% vs 8%, P < 0.001). The LRR of patients with ERAT only in the first 3 days was lower than those with ERAT both in the first 3 days and in 4–90 days (29% vs 64%, P = 0.036).ConclusionsCBA was an effective and safe treatment option for paroxysmal AF. Patients with ERAT had higher LRR after CBA of AF. The time when ERAT occurred had an impact on LRR.
Photodynamic Therapy With Hematoporphyrin Derivative in the Treatment of Superficial Transitional-Cell Carcinoma of the Bladder
Prout, George R., Lin, Chi‐Wei , Benson, Ralph C., Nseyo, U.O., Griffin, Pamela P., Kinsey, J. H. , Tian, Ming , Lao, Yi, Main, Y.-Z., Chen, X. , Qiao, Shuo, Daly, James J. , Tian, M.-E., Lao, Y.-H., Ren, F.-M., Qiao, S.-J.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 139 | Issue: 5 | Pages: 1132-1133

10.1016/s0022-5347(17)42809-6 Get It

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
LaPlant, Betsy, Call, Timothy G. , Leis, José F., He, Rong , Wiseman, Gregory A., Lin, Yi , Asmus, Erik, Nowakowski, Grzegorz S. , Conte, Michael, Bowen, Deborah A., Aitken, Casey N., Dyke, Daniel L. Van , Greipp, Patricia T. , Wu, Xiaosheng , Secreto, Charla, Tian, Shulan , Braggio, Esteban , Wellik, Linda, Micallef, Ivana N. , Viswanatha, David S., Yan, Huihuang , Chanan‐Khan, Asher , Ansell, Stephen M. , LaPlant, Betsy R, Chanan-Khan, Asher A., Ding, Wei , Parikh, Sameer A. , Shanafelt, Tait D. , Sinha, Sutapa , Le‐Rademacher, Jennifer , Feldman, Andrew L. , Habermann, Thomas M. , Witzig, Thomas E. , Liu, Xin , Zhang, Henan , Kay, Neil E. , Dong, Haidong , Braggio, Esteban , Greipp, Patricia T , Lin, Yi

Mayo Clinic

Blood | April 20, 2017 | Volume: 129 | Issue: 26 | Pages: 3419-3427

10.1182/blood-2017-02-765685 | PMID 28424162 Get It

Key Points Pembrolizumab was first shown to be clinically active in CLL patients with RT. PD-1 and PD-L1 expression in tumor microenvironment are promising biomarkers to select RT patients for PD-1 blockade.
Comparative analysis of de novo assemblers for variation discovery in personal genomes
Tian, Shulan , Yan, Huihuang , Klee, Eric W. , Kalmbach, Michael T., Kalmbach, Michael, Slager, Susan L.

Mayo Clinic

Briefings in Bioinformatics | March 16, 2017 | Volume: 19 | Issue: 5 | Pages: 893-904

10.1093/bib/bbx037 | PMID 28407084 Get It

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer
Hampras, Shalaka , Sucheston‐Campbell, Lara, Cannioto, Rikki , Chang‐Claude, Jenny , Dörk, Thilo , Hillemanns, Peter , Preus, Leah, Knutson, Keith L. , Wallace, Paul K. , Friel, Grace , Davis, Warren , Nesline, Mary , Pearce, Celeste Leigh, Kelemen, Linda E. , Goodman, Marc T. , Terry, Kathryn L. , Schoof, Nils , Eng, Kevin H., Clay‐Gilmour, Alyssa , Joseph, Janine M. , Aben, Katja K.H. , Antonenkova, Natalia, Baker, Helen , Bean, Yukie T., Beckmann, Matthias W. , Bisogna, Maria, Bogdanova, Natalia , Brinton, Louise A. , Bruinsma, Fiona , Campbell, Ian , Carty, Karen , Dansonka‐Mieszkowska, Agnieszka , Despierre, Evelyn, Dicks, Ed , Easton, Doug , Eccles, Diana , Edwards, Robert P., Ekici, Arif B. , Fasching, Peter A. , Gao, Yu‐Tang , Harrington, Patricia, Harter, Philipp , Hasmad, Hanis Nazihah, Hein, Alexander , Heitz, Florian , Hildebrandt, Michelle A.T., Høgdall, Claus , Høgdall, Estrid , Hosono, Satoyo , Iversen, Edwin S., Jakubowska, Anna , Jensen, Allan , Ji, Bu‐Tian , Kellar, Melissa, Kelley, Joseph L., Kiemeney, Lambertus A. , Klapdor, Rüdiger , Kolomeyevskaya, Nonna, Krakstad, Camilla , Kruszka, Bridget, Kupryjańczyk, Jolanta , Lambrechts, Diether , Lambrechts, Sandrina, Le, Nhu D. , Lee, Alice W. , Lele, Shashikant , Leminen, Arto, Lester, Jenny, Levine, Douglas A. , Liang, Dong , Lissowska, Jolanta , Liu, Song , Lu, Karen, Lubiński, Jan , Lundvall, Lene, Massuger, Leon F.A.G. , Matsuo, Keitaro , McGuire, V., McLaughlin, John R., McNeish, Iain A. , Menon, Usha , Moes-Sosnowska, Joanna , Narod, Steven A., Nedergaard, Lotte , Nickels, Stefan , Olson, Sara H. , Weber, Rachel Palmieri , Paul, James , Pelttari, Liisa M. , Perkins, Barbara, Permuth‐Wey, Jenny, Pike, Malcolm C., Plisiecka-Hałasa, Joanna, Rossing, Mary Anne, Rothstein, Joseph H. , Runnebaum, Ingo B. , Rzepecka, Iwona K. , Salvesen, Helga B., Schernhammer, Eva , Schmitt, Kristina, Schwaab, Ira, Shvetsov, Yurii B. , Sieh, Weiva , Song, Honglin , Southey, Melissa C. , Tangen, Ingvild L. , Teo, Soo‐Hwang , Thompson, Pamela J., Timorek, Agnieszka, Tworoger, Shelley S. , Altena, Anna M. van, Vergote, Ignace , Vierkant, Robert A. , Walsh, Christine , Wang‐Gohrke, Shan , Wentzensen, Nicolas, Whittemore, Alice S. , Wicklund, Kristine G. , Wu, Anna H. , Wu, Xifeng , Woo, Yin Ling , Zheng, Wei , Gayther, Simon A. , Ramus, Susan J. , Sellers, Thomas A. , Schildkraut, Joellen M. , Phelan, Catherine M., Chenevix‐Trench, Georgia , Cunningham, Julie M. , Ness, Roberta B., Odunsi, Kunle , Goode, Ellen L. , Moysich, Kirsten B., Lu, Karen H. , Lambrechts, Diether , Modugno, Francesmary , Knutson, Keith L. , Hong, Chi‐Chen , Bandera, Elisa V. , Singh, Prashant Kumar , Anton‐Culver, Hoda , Bjørge, Line , Brooks‐Wilson, Angela , Bützow, Ralf C. , Cook, Linda S. , Cramer, Daniel W. , Cybulski, Cezary , Dennis, Joe , Doherty, Jennifer A. , Bois, Andreas du , Dürst, Matthias , Fridley, Brooke L. , Gentry‐Maharaj, Aleksandra , Giles, Graham G. , Glasspool, Rosalind , Gronwald, Jacek , Hildebrandt, Michelle A.T. , Karlan, Beth Y. , Kjær, Susanne K. , Lu, Karen, McLaughlin, John R., Nevanlinna, Heli , Orlow, Irene , Pejovic, Tanja B. , Poole, Elizabeth M. , Risch, Harvey A. , Rudolph, Anja , Shu, Xiao‐Ou , Siddiqui, Nadeem , Tyrer, Jonathan P. , Wentzensen, Nicolas , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Berchuck, Andrew , Pharoah, Paul D.P. , Pelttari, L M , Dörk, Thilo , Lambrechts, Diether , Kiemeney, Lambertus A , McNeish, Iain A , Ramus, Susan J , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Paul, James , Moysich, Kirsten , Lissowska, Jolanta , Campbell, Ian G , Southey, Melissa C , Matsuo, Keitaro , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Zheng, Wei , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Oncotarget | July 6, 2016 | Volume: 7 | Issue: 43 | Pages: 69097-69110

10.18632/oncotarget.10215 | PMID 27533245 Get It

Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis
Yang, Zhen , Oishi, Hisashi , Matteson, Eric L. , Tian, Lü , Goronzy, Jörg J. , Weyand, Cornelia M. , Shen, Yi , Goronzy, Jorg

Mayo Clinic

Science Translational Medicine | March 23, 2016 | Volume: 8 | Issue: 331 | Pages: No page available

10.1126/scitranslmed.aad7151 | PMID 27009267 Get It

ROS deficiency promotes proinflammatory T cells in rheumatoid arthritis.
Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm
Sun, Xiangqing , Elston, Robert C. , Barnholtz‐Sloan, Jill S. , Faulx, Ashley L., Mittal, Sumeet K. , Shaheen, Nicholas J. , Wang, Jean S. , Iyer, Prasad G. , Tian, Ye D. , Willis, Joseph , Guda, Kishore , Markowitz, Sanford D. , Chandar, Apoorva K., Warfe, James M. , Brock, Wendy , Chak, Amitabh , Falk, Gary W. , Grady, William M. , Canto, Marcia Irene , Abrams, Julian A , Willis, Joseph E , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 29, 2016 | Volume: 25 | Issue: 5 | Pages: 727-735

10.1158/1055-9965.epi-15-0832 | PMID 26929243 Get It

Abstract Background: Barrett's esophagus is often asymptomatic and only a small portion of Barrett's esophagus patients are currently diagnosed and under surveillance. Therefore, it is important to develop risk prediction models to identify high-risk individuals with Barrett's esophagus. Familial aggregation of Barrett's esophagus and esophageal adenocarcinoma, and the increased risk of esophageal adenocarcinoma for individuals with a family history, raise the necessity of including genetic factors in the prediction model. Methods to determine risk prediction models using both risk covariates and ascertained family data are not well developed. Methods: We developed a Barrett's Esophagus Translational Research Network (BETRNet) risk prediction model from 787 singly ascertained Barrett's esophagus pedigrees and 92 multiplex Barrett's esophagus pedigrees, fitting a multivariate logistic model that incorporates family history and clinical risk factors. The eight risk factors, age, sex, education level, parental status, smoking, heartburn frequency, regurgitation frequency, and use of acid suppressant, were included in the model. The prediction accuracy was evaluated on the training dataset and an independent validation dataset of 643 multiplex Barrett's esophagus pedigrees. Results: Our results indicate family information helps to predict Barrett's esophagus risk, and predicting in families improves both prediction calibration and discrimination accuracy. Conclusions: Our model can predict Barrett's esophagus risk for anyone with family members known to have, or not have, had Barrett's esophagus. It can predict risk for unrelated individuals without knowing any relatives' information. Impact: Our prediction model will shed light on effectively identifying high-risk individuals for Barrett's esophagus screening and surveillance, consequently allowing intervention at an early stage, and reducing mortality from esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 25(5); 727–35. ©2016 AACR.